04.06.06
Gemin X Biotechnologies achieved positive preclinical study results evaluating GX15-070 both as a monotherapy and in combination with the proteasome inhibitor Velcade for the treatment of mantle cell lymphoma (MCL). The data demonstrated that GX15-070 induced apoptosis and exhibited synergistic effects with Velcade.
In the preclinical study, GX15-070 as a single agent induced apoptosis in vitro in MCL cells lines and in primary cells from MCL patients, with 9 out of 12 patient samples showing strong sensitivity to GX15-070. GX15-070 was also evaluated in combination with Velcade, which has shown promising results in MCL treatment but can also induce the intracellular accumulation of the MCL-1, leading to resistance. The combination of GX15-070 and Velcade resulted in a synergistic effect, allowing a reduction in the dose of Velcade required to kill cancer cells. No cytotoxic affects were observed in non-cancerous cell lines, suggesting that GX15-070 may represent an attractive new investigational therapeutic option for the treatment of MCL.
In the preclinical study, GX15-070 as a single agent induced apoptosis in vitro in MCL cells lines and in primary cells from MCL patients, with 9 out of 12 patient samples showing strong sensitivity to GX15-070. GX15-070 was also evaluated in combination with Velcade, which has shown promising results in MCL treatment but can also induce the intracellular accumulation of the MCL-1, leading to resistance. The combination of GX15-070 and Velcade resulted in a synergistic effect, allowing a reduction in the dose of Velcade required to kill cancer cells. No cytotoxic affects were observed in non-cancerous cell lines, suggesting that GX15-070 may represent an attractive new investigational therapeutic option for the treatment of MCL.